In an adult with obsessive‑compulsive disorder who has failed an adequate trial of a selective serotonin reuptake inhibitor (SSRI) or clomipramine and completed exposure and response prevention, is EMDR (eye movement desensitization and reprocessing) an appropriate treatment option?

EMDR is Not an Appropriate Treatment Option for Treatment-Resistant OCD

EMDR (eye movement desensitization and reprocessing) is not recommended for obsessive-compulsive disorder and does not appear in evidence-based treatment guidelines for OCD, including for treatment-resistant cases. 1

Evidence-Based Options for Treatment-Resistant OCD

After failing an adequate trial of SSRI/clomipramine and completing exposure and response prevention (ERP), the following strategies have established efficacy:

First-Line Augmentation Strategies

Pharmacological augmentation with antipsychotics is the most commonly used and evidence-based approach for SSRI-resistant OCD 1:

• Risperidone and aripiprazole have meta-analytic evidence supporting their efficacy 1
• Only one-third of patients with SSRI-resistant OCD show clinically meaningful response to antipsychotic augmentation 1
• Monitor closely for weight gain and metabolic dysregulation 1

Augmentation with CBT/ERP produces larger effect sizes than antipsychotic augmentation when feasible 1:

• This is the preferred augmentation strategy if the patient can tolerate exposure therapy 1
• Some patients cannot tolerate or access CBT/ERP 1

Second-Line Pharmacological Strategies

Switching strategies 1:

• Switch to a different SSRI 1
• Use higher than maximum recommended SSRI doses 1
• Trial of serotonin-noradrenaline reuptake inhibitor 1

Clomipramine augmentation of SSRIs 1:

• In the only head-to-head trial, fluoxetine plus clomipramine was superior to fluoxetine plus quetiapine 1
• Critical safety concern: This combination increases blood levels of both drugs, risking seizures, cardiac arrhythmia, and serotonergic syndrome 1, 2
• Time on SSRI monotherapy (6 months) was the most important predictor of response 1

Glutamatergic augmentation agents 1:

• N-acetylcysteine has the largest evidence base (3 of 5 RCTs positive) 1
• Memantine has demonstrated efficacy in multiple trials 1
• Other agents (lamotrigine, topiramate, riluzole, ketamine) have some evidence but require further study 1

Neuromodulation for Severe Refractory Cases

For patients who fail multiple medication trials 1:

• Deep repetitive transcranial magnetic stimulation (rTMS) is FDA-approved for OCD 1
• Targets include supplementary motor cortex, dorsolateral prefrontal cortex, medial prefrontal cortex, and anterior cingulate cortex 1
• Deep brain stimulation (DBS) is reserved for very intractable cases (less than 1% of treatment-seeking individuals) 1
• Approximately 30-50% of patients with severe refractory OCD respond to DBS 1

Why EMDR Is Not Recommended

The comprehensive Nature Reviews Disease Primers guideline on OCD explicitly categorizes alternative treatments separately from evidence-based interventions 1:

• Alternative treatments mentioned include yogic meditation, mindfulness-based CBT, physical exercise, and acupuncture 1
• The guideline states: "further data are needed before these treatments can be routinely recommended as evidence-based interventions" 1
• EMDR is not even mentioned among alternative treatments for OCD 1

Clinical Algorithm for This Patient

1. Ensure adequate prior treatment: Verify the SSRI/clomipramine trial was at sufficient dose for 8-12 weeks and ERP was delivered by a trained clinician 1

2. If prior treatment was adequate, augment with CBT/ERP if not already maximized or if patient can now tolerate it 1

3. If CBT/ERP augmentation not feasible, add antipsychotic augmentation (risperidone or aripiprazole) 1

4. If antipsychotic augmentation fails, consider:

   • Switching to different SSRI or higher dose 1
   • N-acetylcysteine or memantine augmentation 1
   • Clomipramine augmentation (with careful monitoring for drug interactions and serious adverse events) 1, 2

5. For severe refractory cases after multiple failed trials, refer for neuromodulation evaluation (rTMS or DBS) 1

Common Pitfalls

• Do not pursue EMDR as it lacks evidence in OCD and delays access to proven treatments 1
• Ensure adequate duration (8-12 weeks minimum) and dosing of prior SSRI trials before declaring treatment resistance 1
• Monitor for seizure risk when using clomipramine, especially in combination with SSRIs (maximum 250 mg/day in adults) 2
• Screen for bipolar disorder before initiating or augmenting antidepressants 2